NeuroOne submits FDA filing early for trigeminal nerve ablation using its OneRF system as the facial pain market sees projected growth to $416 million by 2030.

The following is a summary of “Suicidal Ideation and Self-Injury in Trigeminal Neuralgia,” published in the April 2025 issue ...

NeuroOne (Nasdaq:NMTC) announced today that it filed an FDA 510(k) submission for its trigeminal nerve ablation technology.